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Abstract
Swertiamarin is a secoiridoid glycoside found extensively in Enicostemma littorale and Swertia chirata belonging to the family of
Gentianaceae, which has been reported to cure many diseases including diabetes, hypertension, atherosclerosis, arthritis, malaria and
abdominal ulcers. The present review aimed to compile up-to-date information on the progress made in the protective role of
swertiamarin and its metabolites such as gentianine and erythrocentaurin in diabetes mellitus and related complications to provide a
guide for future research on this bioactive molecule. Information on the swertiamarin was collected from major scientific databases
(Pubmed, Springer, Google Scholar and Web of Science) for publication in1974-2020. In this review, the role of swertiamarin and its
metabolites in the management of diabetes mellitus and related complications was discussed. Swertiamarin and its metabolites reported
exhibiting a wide range of biological activities such as antidiabetic, anti-atherosclerotic, anti-inflammatory and antioxidant effects. These
activities were mainly due to their effect on various signalling pathways associated with swertiamarin such as PPAR-gene upregulation,
P-407-induction, inhibition of HMG-Co A reductase, LDL oxidation, lipid peroxidation markers and stimulation of antioxidant enzymes.
Swertiamarin and its metabolites exhibit a wide range of biological activities. This review presents evidence supporting the point of view
that swertiamarin should be considered a potential therapeutic agent for the management of diabetes mellitus and related complications,
giving rise to novel applications in their prevention and treatment.
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INTRODUCTION
Diabetes mellitus is a chronic metabolic disease that has
a significant impact on the health, quality of life and life
expectancy of patients as well as on the healthcare system. It
is associated with several other metabolic abnormalities such
as obesity, hypertension and dyslipidaemia, which contributes
to the  very  high  rate  of  cardiovascular  morbidity  and
mortality1. There is an explosive increase in the number of
people diagnosed with diabetes worldwide. India is one of the
6 countries of the International Diabetes Federation (IDF)
South-East Asia (SEA) region. The 415 M people have diabetes
in the world and 78 M people in the SEA region, by 2040 this
will rise to 140 M. There were 69.1 M cases of diabetes in India
in 2015 (IDF)1. Epidemiological studies have demonstrated
that obesity  associated  with  inflammation,  hypertension
and other metabolic aberrations are a major risk factor for
diabetes mellitus and cardiovascular disease. Cardiovascular
complications are the leading cause of morbidity and
mortality in patients with type 2 diabetes2,3. The relationship
between tissue insulin resistance and compensatory
hyperinsulinemia cause early atherosclerosis and an increased
cardiovascular risk for the non-insulin-dependent diabetic
patient4. Sowers et al.5 suggest diabetic patient with
cardiovascular complication has a high mortality rate and
hypertension is commonly found in diabetes patients than
non-diabetes patients. Accelerated atherosclerotic vascular
disease is the leading cause of mortality in patients with
diabetes mellitus. The increases of oxidative injury in diabetes
mellitus patients associated with a weakened defence due to
reduced endogenous antioxidants6.
Current therapy to alleviate diabetes mellitus and related
complications (such as cardiovascular complications, diabetic
retinopathy, diabetic neuropathy and diabetic nephropathy)
is not optimal and thus efforts have been made to develop
effective and better drugs, which led to the discovery of
natural agents. Herbal remedies are natural products derived
from plants and plant products that have been traditionally
used to treat various diseases7. During the last decade, the use
of traditional medicine has expanded globally and it’s gaining
popularity. Herbs have been widely used for therapeutic
purpose due to the expensive and unaffordable of the
conventional drug in the rural area because herbal remedies
are readily available and cheap. According to the WHO, herbal
medicines serve the health needs of about 80% of the world’s
population, especially for millions of people in the vast rural
areas of developing countries. The WHO Expert Committee on
diabetes has recommended that traditional medicinal herbs
be systematically investigated8.
Many researchers are focusing on natural products and
their secondary metabolites in search of new drugs for the
management of diabetes mellitus and related complications.
Among these secondary metabolites, swertiamarin a
secoiridoid glycoside, the main component of plants such as
Enicostemma littorale has attracted more attention due to its
ability to exert beneficial effects in various pathological
conditions. The E. littorale  locally   known   as  Chota-chiretta
in India is a commonly used Ayurvedic medicine for the
treatment of diabetes9. It is a glabrous perennial herb and
found throughout India. The E. littorale is known for several
medicinal uses including antidiabetic, hypolipidemic and
antipyretic. It is also reported as a digestive, liver tonic, urinary
astringent and anti-periodic. It is useful in dyspepsia,
flatulence, colic, abdominal ulcers, constipation, intermittent
fevers, malaise and pruritus10. However, to the best of our
knowledge, to date, systemic studies to understand the
molecular basis of diabetes and related complications
preventing properties of the active constituent of E. littorale
(swertiamarin) has not been reported. Hence, the present
review aimed to compile up-to-date information on the
progress made in the protective role of swertiamarin in
diabetes mellitus and related complications to provide a guide
for future research on this bioactive molecule. Hence, this
study based on the collection of research articles related to
swertiamarin from various scientific databases and a systemic
review of its potential pharmacological role in the
management of diabetes mellitus and related cardiovascular
complications.
METHODOLOGY
The information on the swertiamarin in diabetes mellitus
and related complications were collected from several
databases such as Science direct, Pubmed, NCBI, Springer and
Google scholar etc., from 1974-2016. Some information also
collected from official websites, such as IDF and WHO. The
keywords used for the searching, such as swertiamarin and
diabetes mellitus, swertiamarin and antihyperlipidaemic
activity, swertiamarin and antioxidant activity, swertiamarin
and anti-inflammatory activity, swertiamarin and nephropathy
and metabolism and pharmacokinetics of swertiamarin.
Potential  pharmacological  activity  of  swertiamarin:
Swertiamarin (Fig. 1) is a secoiridoid glycoside derived from
loganic acid through mevalonic acid pathway. It is distributed
predominantly among the members of Gentianaceae, mainly
Enicostemma  littorale  Blume  and Swertia chirata  Roxb.
Some specific  activities  have been reported for swertiamarin 
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Fig. 1: Chemical structure of swertiamarin11
such  as  anticholinergic,  antihyperlipidemic,   insulinotropic,
antinociceptive, antioxidant and hepatoprotective10. This
review provides an overview of the swertiamarin role in the
management and treatment of diabetes mellitus and related
complications.
E. littorale has a long history of human use in traditional
medicine throughout India. There are a plethora of reports of
experimental and  clinical pieces of evidence related to various
pharmacological  activities  of E. littorale and swertiamarin.
Up-dated  information  summarized  in Table 1 (potential 
pharmacological  activity of swertiamarin  in pre-clinical study)
and Table 2 (clinical efficacy of E. littorale  in diabetic patient).
Antidiabetic activity:  The authors establish the effectiveness
of swertiamarin in achieving glucose homeostasis via
inhibition of carbohydrate metabolizing enzymes by in vitro
and  in vivo  studies. Swertiamarin was effective in inhibiting
"-amylase and "-glucosidase with IC50 values of 1.29±0.25
and 0.84±0.11 mg mLG1, respectively. The studies in starch
and sucrose challenged mice showed that swertiamarin
effectively restricted the increase in the peak Blood Glucose
Level (BGL). The increase in peak BGL was 49 and 57 mg dLG1
only in the treatment groups compared to 70 and 80 mg dLG1
in untreated groups after 30 min in starch and sucrose-fed
mice, respectively11. Same group isolated erythrocentaurin
from the ethyl acetate fraction of E. littorale using medium-
pressure liquid chromatography. The method consisted of a
simple step gradient from 10-20% ethyl acetate in n-hexane.
Isolated erythrocentaurin was evaluated for "-amylase
inhibition  activity,  it  exhibited  a  concentration-dependent
"-amylase  inhibition  (IC50  1.67±0.28 mg mLG1)12.
Dhanavathy et al.13 have investigated the effect of
swertiamarin  in   diabetic  Wister  rat.  Swertiamarin at 15, 25,
50 mg kgG1 b.wt., in 28 days, has significantly reduced fasting
blood glucose, glycated haemoglobin (HbA1c), total
cholesterol, triglycerides, LDL and increase the plasma insulin,
HDL levels and body weight as compared to STZ-induced
diabetic rats. The pancreas of swertiamarin treated diabetic
rats showed  regeneration  of  islets   when   compared  to STZ-
induced diabetic rats as confirmed by immunohistological
studies.
Phoboo et al.14 have reported the antidiabetic activity of
swertiamarin isolated from Swertia chirayita. The crude
aqueous and 12% ethanolic extracts of Swertia chirayita
showed a moderate-to-high positive correlation between
antioxidant activity and total phenolic content and moderate-
to-high "-glucosidase inhibitory activity. The hexane fraction
of Swertia chirayita has local healing and antihyperglycemic
potential due to the presence of three main phytochemicals
mainly  swertiamarin,   mangiferin  and  amarogentin.
Swertiamarin has shown to modulate 5-HT2 receptor and
hypolipidemic potential in animal models of depression,
diabetes  and  obesity15.  In-silico  studies  performed  by
Vaidya et al.16 reported that swertiamarin, secoiridoid
glycoside has been shown to possess antidiabetic activity
through inhibiting glycogen phosphorylase-a at pyridoxal
phosphate   binding    site    with    its     docking     energy   of
-7.01 kcal moLG1. Swertiamarin  and  its  derivatives confer
anti-diabetic and anti-hyperlipidemic effects17. Maroo et al.18
reported the dose-dependent blood-glucose-lowering effect
of the aqueous extract of E. littorale in alloxan-induced
diabetic rats. A dose of 1.5 g dry plant equivalent extract per
100 g body weight resulted in a significant increase in serum
insulin levels without producing any toxic effects as compared
to diabetic control rats. The effect was mainly attributed
regeneration of $-cells in  the  pancreas and stimulating
insulin  release19.   An   aqueous  extract  of  E.  littorale  when
administered to streptozotocin (STZ)-induced neonatal
NIDDM rats in the dose of 2 g kgG1 orally for 6 weeks, resulted
in a significant decrease in fasting BGL in glucose fed rats.
Insulin sensitivity was found to be significantly increased after
treatment with E. littorale along with a decrease in elevated
cholesterol, triglyceride and creatinine values of NIDDM rats20.
A herbo-mineral  formulation  containing  E.  littorale exhibited
antihyperglycemic   and   antioxidant   activities when
administered orally to STZ-induced diabetic rats at doses of
100 and 200 mg kgG1 continuously for 45 days. Significant
improvement in blood glucose tolerance was also observed21.
Clinical  efficacy  in  the  diabetic  patient: The fresh juice of
E. littorale  (1-5 ounce three times a day along with the
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of diabetic patients22. In another study, the antidiabetic
efficacy  of the aqueous extract of the E. littorale was
examined in newly diagnosed NIDDM patients taking only the
extract and was administered as two divided doses, 30 min
before the meal as 5 g aqueous extract per single dose. Out of
the 20 patients who volunteered, 11 completed the 2 month
trial and a decrease in fasting and postprandial blood glucose
and glycosylated haemoglobin levels were observed along
with an improvement in the antioxidant parameters of the
patients. There was also an increase in serum insulin levels in
7 patients after extract treatment as compared to levels before
treatment. Serum total cholesterol and serum triglyceride
levels were decreased significantly with a significant increase
in serum HDL cholesterol levels23. Upadhyay and Goyal24
demonstrated the efficacy of E. littorale (250 mg pilLG1) twice
a day for  3 months in preventing various complications
arising in type 2 diabetic patient (n = 84). At the end of the
treatment, blood glucose and serum insulin levels of type 2
diabetic patients were significantly reduced from 205±10.2-
150±6.8 mg dLG1 and 99.8±8.6-73.2±6.3 MCU mLG1,
respectively. It also significantly reduced urine sugar, systolic
blood pressure  as  well  as  pulse  rate.  Also,  treatment
significantly reduced serum creatinine, cholesterol and
triglyceride levels along with a significant increase in serum
HDL levels. These results suggest that E. littorale provided
amelioration of the hyperglycemic and hyperinsulinaemic
conditions of diabetic patients. The therapeutic potential of
standardized aqueous extract of E. littorale  was evaluated in
metabolic syndrome patients (n = 50). Patients were
randomized to either placebo or aqueous extract of E. littorale
(500 m three times a day in addition to ongoing conventional
treatment  for  3  months  with  follow  up  o  1  month).  The
E. littorale treatment showed a significant decline in fasting
blood sugar, postprandial blood sugar, serum cholesterol,
triglyceride, LDL, VLDL levels and the significant increase in
HDL levels. These results suggest that E. littorale exhibit
excellent hypoglycemic and hypolipidemic potential in
metabolic syndrome patients25.
Cardioprotective   and   antihyperlipidemic  activity:
Swertiamarin  has  been  reported  to  have high anti-
atherogenic, cholesterol-lowering potential and inhibition of
HMG-Co-A reductase26. The antihyperlipidaemic effect of
swertiamarin is carried out in a rat model of hyperlipidaemia
induced by P-407 (Poloxamer-407), a non-ionic surfactant.
Studies have reported that swertiamarin decreases serum
cholesterol levels and reduced the oxidation of LDL. Besides,
swertiamarin has also shown to have the ability in increasing
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Swertiamarin  (50  mg  kgG1, i.p.) administered once a day for
6 weeks resulted in significant reductions in serum
triglycerides, cholesterol and low-density lipoprotein levels in
diabetic animals. Serum fasting glucose was significantly
decreased, moreover, the insulin sensitivity index was
significantly increased in swertiamarin treated animals28.
Swertiamarin treatment is reported to have no significant
effect on adipogenesis or the mRNA expression of PPAR-g and
GLUT-4,  however, there was a significant increase in the
mRNA expression of adiponectin. Treatment with gentianine,
active metabolite of swertiamarin significantly increased
adipogenesis, which was associated with a significant increase
in the mRNA expression of PPAR-g, GLUT-4 and adiponectin29.
The non-fasting glucose level in Zucker rats was
significantly reduced with the treatment of swertiamarin but
AUCglucose showed small changes. The serum cholesterol
and triglyceride also reduced in swertiamarin treated rats.
Insulin can activate the lipoprotein lipase and hydrolyses
triglycerides. Therefore, insulin deficiency causes the
inactivation of lipoprotein lipase and result in dyslipidemia.
When swertiamarin is used at 75 mg kgG1 day i.p., for 28 days,
the serum glucose, cholesterol, triglycerides, non-esterified
free fatty acid, urea and matrix metalloproteinase 3 and 9
(MMP 3 and MMP 9) has been shown significant reduction
than untreated Zucker fa/fa rat and these results suggest that
the decrease in serum MMP 9 and MMP 3 levels are one of the
possible  mechanism responsible for the improvement of
these complications by swertiamarin30. The aqueous extract of
E. littorale showed a cardioprotective and antihypertensive
effect in fructose-fed rats. High fructose-fed rats treated with
E. littorale showed improved insulin resistance, along with
reduced hypertriglyceridemia, hypertension, platelet
agreeability, blood coagulation, serum enzymes (CK-MB,
SGOT, LDH  and  SGPT)  and  vascular reactivity31. The aerial
part   of    E.    littorale   showed   a   hypolipidaemic   effect  in
p-dimethylamino benzene induced hepatotoxic animals32.
Antioxidant activity: In an in vitro study, swertiamarin
showed antioxidant activity by scavenging hydroxyl radicals,
H2O2 superoxide radicals and inhibiting lipid peroxidation and
nitric oxide radical33. Furthermore, studies conducted by
Jaishree and Badami34, by using D-galactosamine induced
acute liver damage in rats. The D-galactosamine caused
significant hepatotoxicity by alteration of several hepatic
parameters.  It  also  caused  significant   lipid  peroxidation
and reduced the levels of antioxidant defence mechanisms.
The elevated  levels  of  CAT,  SOD  and  GSH and reduced
levels of  thiobarbituric   acid   reactive  substances  were
observed in  serum,   liver   and   kidney   after   treatment  with
swertiamarin  (100  and  200  mg kgG1 b.wt.) for 8 days before
D-galactosamine. Other than that, D-galactosamine
intoxicated rats have been shown to reduce hepatic damage
with bile duct proliferation with swertiamarin treatment.
These  observations  suggest  that  swertiamarin restored
these  antioxidant   mechanisms   in   the damage caused by
D-galactosamine. The aqueous extract of E. littorale  at a dose
of 1.5 g per 100 g b.wt., decreased the activities of erythrocyte
catalase and superoxide dismutase and lipid peroxidation
levels, with the increase in glutathione levels in
hypercholesterolaemic rats35. Oral administration of aqueous
extract of the whole plant (1 and 2 g kgG1, 45 days)
significantly decreased blood glucose, thiobarbituric acid
reactive substances, hydroperoxides and increased
glutathione, superoxide dismutase, catalase and glutathione
peroxidase in liver, kidney and pancreas of alloxan diabetic
rats36.
Anti-inflammatory    activity:     Swertiamarin     (100    and 
200 mg kgG1 b.wt.,) showed antiedematogenic activity in
carrageenan, formalin and histamine-induced paw oedema in
albino rats33. Saravaran et al.37 demonstrated the anti-arthritic
efficacy of swertiamarin in adjuvant arthritis animal model by
the estimation of biochemical parameters, proinflammatory
cytokines and enzymes along with histopathological and
radiographic  observations. They reported that swertiamarin
(2, 5, 10 mg kgG1 b.wt.)  significantly abolished inflammation
by regulating toxic substances like lysosomal enzymes, free
radicals, bone destructive enzymes and paw thickness of
arthritic animals. The histopathological and radiological
evidence supported the curative effect of swertiamarin on
bone destruction and confirmed the recovery of treated
animals through balancing inflammatory mediators in the
arthritic joint. The treatment significantly diminished the
protein levels of p65 NF-5b, p-IκB", a p-STAT3 and p-JAK2
transcription factor in animals as well as LPS induced RAW
264.7 macrophage cells. The release of proinflammatory
cytokines  (IL-1,  TNF,  IL-6) and proangiogenic enzymes
(MMPs, iNOS, PGE2, PPARγ and COX-2) were decreased and
significantly  increased  the  levels of anti-inflammatory
proteins (IL-10, IL-4) in the swertiamarin treated groups when
compared to the disease group. These results suggest that the
swertiamarin inhibited the development of arthritis by
modulating NF-5B/IκB, JAK2/STAT3 signalling and thus it acts
as an anti-arthritic agent.
Saravaran et  al.38 in another study evaluated the anti-
inflammatory potential of swertiamarin in IL-1$ induced
Fibroblast Like Synoviocytes (FLS) which was isolated from
Freund’s Complete Adjuvant Induced Arthritic (AIA) rats. Both
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the normal FLS and AA-FLS were used for the experiment and
its efficacy was estimated in terms of mRNA and protein
expression levels of inflammatory and osteoclastogenesis
mediators. Results indicated that IL-1$ induced cell
proliferation (149.46±13.73%) and NO production
(162.03±11.03%) in AA-FLS was abolished after treatment
with swertiamarin.   Swertiamarin   also  significantly 
modulated the expression of apoptotic marker (caspase 3),
proinflammation mediators (TNF-", IL-6, PGE2, COX-2, iNOS,
MMPs) and osteoclastogenic mediator (RANKL) at both the
mRNA and protein levels. Further, treatment with
swertiamarin inhibited the levels of p38 MAPK" in a dose-
dependent manner and also significantly attenuated the
release of the same in a time-dependent mode. This finding
suggests that treatment with swertiamarin attenuated IL-1$
induced FLS and it revealed anti-inflammatory potential by
attending aggressive FLS.
In vivo  and in vitro  study on immunomodulatory activity
of swertiamarin (2, 5, 10 mg kgG1 b.wt.) was further conducted
by Saravaran et al. 39 In vivo activity was estimated in Sheep
Red Blood Cell (SRBC) model by the assessment of
Hemagglutinating Antibody  (HA)  titer, effect on organ
weight, Plaque-Forming Cells (PFC) assay, Delayed-Type
Hypersensitivity (DTH) reaction and quantitative hemolysis of
SRBC. Whereas, the in vitro studies were done on isolated
splenocytes,  neutrophils and peritoneal macrophages. In an
in vivo study, swertiamarin treated animal showed a
significant increase in HA titer, PFC and weight of the spleen
and thymus, however, the immune-inflammatory reaction was
reduced in the DTH reaction. In an in vitro study, mRNA and
protein levels of Th2-mediated cytokines (IL-4 and IL-10) are
elevated,  whereas  the  levels  of Th1-mediated cytokines
(TNF-", IL-1$ and IL-6) in Con A-stimulated splenocytes were
reduced with swertiamarin treatment. Further, swertiamarin
inhibited  the  release  of  free  radicals  significantly in
phytohemagglutinin-induced   neutrophils   and  also
ameliorated   the  mRNA  and  protein  expression of
proinflammatory  cytokines   (TNF-",   IL-1$  and IL-6) in
lipopolysaccharide (LPS)-induced macrophages and these
results confirmed that swertiamarin acted as an anti-
inflammatory  mediator.  The  E.  littorale  was found to exert
54 and 30% anti-inflammatory activity in carrageenan-induced
acute inflammation and chronic inflammation of cotton pellet
granuloma respectively. The alcoholic extract was found to be
effective on human erythrocyte membrane stabilization and
inhibition of cobra venom phospholipase A2 and the effect
was found to be comparable to the standard anti-
inflammatory drug, hydrocortisone40.
Swertiamarin  in   diabetic   nephropathy:  Diabetic
nephropathy was assessed by serum urea, creatinine, lipid
profile  and  water  intake   levels.   The   aqueous   extract   of
E. littorale treatment significantly prevented the loss in body
weight, water intake and food consumption. Swertiamarin
significantly revered the elevated glucose level in STZ induced
diabetic rats. Also, aqueous extract of E. littorale can inhibit
HMG-CoA  reductase  action  which  is  the limiting factor of
the  LDL  metabolism.  Treatment   with  aqueous  extract  of
E. littorale (1 g kgG1, p.o.) and swertiamarin (50 mg kgG1, p.o.)
daily for 3 weeks in type 1 diabetic nephropathy complications
in Sprague-Dawley rats significantly decreased serum urea
and creatinine and other parameters associated with the
development of diabetic nephropathy in type 1 diabetic rats.
Besides, considerable improvement in the histology of
glomerular function has been observed in animals treated
with the aqueous extract of E. littorale and swertiamarin.
Besides that, SGPT and SGOT levels were decreased in type 1
diabetes rats treated with an aqueous extract of E. littorale41.
Metabolism and pharmacokinetic perspective of
swertiamarin: The metabolism of swertiamarin conducted by
using human intestinal bacteria (Proteus mirabilis). This
bacterium enables the swertiamarin to metabolize into
gentianine, erythrocentaurin and 5-(hydroxymethyl)-
isochroman-1-one42 as presented in Fig. 2.
Wang et al.43 investigated the metabolic fate of
swertiamarin in Wister rats by using liquid chromatography/
ion trap mass spectrometry. The results showed two new
metabolites of swertiamarin (1), (R)-gentinol (4a) and (S)-
gentnol (4b) in rat plasma together with known metabolite
gentianine (2). The authors also prepared (R)-gentinol (4a) and
(S)-gentnol (4b) metabolites from stereoselective reduction of
gentianone (3) which is and oxidation product of gentianine
(2) as presented in Fig. 3.
Li et al.44 demonstrated that swertiamarin showed rapid
absorption, elimination and high concentrations were found
in the liver and kidneys, indicating that swertiamarin was
rapidly metabolized in the liver and eliminated by the kidneys.
By using LC-ESI-MS/MS method the plasma concentration-
time profile of swertiamarin (20 and 50 mg kgG1) has been
obtained in SD-rats and the pharmacokinetic parameters have
been calculated. Study results showed that swertiamarin was
rapidly absorbed into blood circulation after administration.
Based upon results, swertiamarin required 0.95 hrs to reach
peak concentration (1920.1 mg mLG1) and half-life was less
than 1.50  hrs.  Wang  et  al.45  reported   that  swertiamarin 
was biotransformed  to  erythrocentaurin  and  3,4-dihydro-5-
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Fig. 2: Metabolites of swertiamarin42
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(hydroxymethyl) isochroman-1-one by human intestinal
bacteria.  Xu  et  al.46  studied  the  pharmacokinetics of
swertiamarin  alone  and  co-administration with oleanolic
acid. In the previous study, it has shown swertiamarin is
rapidly absorbed into blood circulation. When swertiamarin
co-administered with oleanolic acid, both peak plasma
concentration and AUC were reduced while both clearance
and apparent volume of administration were increased. This
indicates oleanolic acid could reduce the bioavailability of rats
due to drug-drug interaction.
An in vivo metabolism study of swertiamarin has been
performed by Wu et al.47 by using 2,4-dinitrophenylhydrazine
derivatization.  The  main  metabolite of swertiamarin which
is erythrocentaurin has been detected after oral
administration of swertiamarin. This study proposed that
swertiamarin undergoes hydrolysis to give aglycone by
bacterial $-glucosidase, which is readily converted to
erythrocentaurin.  Vaidya  et  al.26  revealed that gentianine is
an active metabolite of swertiamarin that possesses a
pharmacophoric moiety. They explored whether the
antidiabetic  effect  of  swertiamarin is due to gentianine,
using 3T3-L1 cells. They found that gentianine significantly
increased adipogenesis by upregulating the mRNA expression
of PPAR-γ, GLUT-4 and adiponectin while swertiamarin
treatment had no significant effect on adipogenesis however,
there was a significant increase in the mRNA expression of
adiponectin. These results suggest that antidiabetic effect of
swertiamarin in in vivo is possibly due to active metabolite
gentianine.
Quantitative estimation of swertiamarin in different
samples: Given the importance of E. littorale in traditional
systems of medicine, several analytical methods have been
reported for the estimation of its bioactive components
(swertiamarin) and its quality assessment. An HPLC method for
estimation of swertiamarin in methanolic extract of E. littorale
and marketed formulations was developed and validated. The
mobile phase composed of methanol and waters (90:10 v/v)
with the retention time of 10.15±1.52 min. The method was
found precise and accurate for the estimation of swertiamarin
in methanolic extract and marketed formulation48.
An HPLC-ESI-MS method has been reported for the
simultaneous determination of four iridoid glycosides in a
formulated preparation composed of 10 ingredient herbs,
with  iridoids  as  the  main  bioactive  components. The
sample preparation for quantification comprised of a simple
ultrasonic extraction and the satisfactory chromatographic
separation  of   the   four   structurally  similar iridoid glycosides
was  affected  in   less   than  3  min  on  a  C18  column  (3 µm,
100×2.0 mm), using an elution system of 10% methanol49.
The HPTLC densitometry method has been developed for the
analysis of swertiamarin in methanolic extract of E. littorale
and commercial formulations. The method was employed
with a high degree of precision and accuracy for the
estimation of swertiamarin in methanolic extract of E. littorale
and commercial formulations50. An LC-MS/MS method was
developed for the simultaneous estimation of two bioactive
markers, mangiferin and amarogentin along with three other
components, amaroswerin, sweroside and swertiamarin in rat
plasma using kutkoside as an internal standard.  The method
was successfully applied to generate a pharmacokinetic profile
of markers as well as to detect other components in plasma
after intravenous dose administration of herbal preparation
containing secoiridoids in male Sprague-Dawley rats51.
An HPLC method has been reported for the simultaneous
determination of swertiamarin and its two metabolites,
erythrocentaurin  and  (5Z)-5-ethylidene-8-hydroxy-3,4,5,6,7,8-
hexahydro-1H-pyrano [3,4-c] pyridin-1-one (M1) in Aspergillus
niger. The chromatographic  separation  was achieved on a
C18 ODS column by gradient elution with 0.04% formic acid
in water and  0.04%  formic  acid  in  acetonitrile as the
gradient mixtures. The retention times of swertiamarin,
erythrocentaurin and M1 were 14.6, 16.8 and 24.8 min,
respectively. The  method  was applied for the quantification
of swertiamarin  and  its  two metabolites during the
fermentation process and the evaluation of the
bioavailabilities52. Chia-Ming L et al.53 developed a liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
method  for  the   simultaneous   determination  of
gentiopicroside, geniposide, baicalin and swertiamarin in rat
plasma. To avoid the stress caused by restraint or anaesthesia,
a freely moving rat model was used to investigate the
pharmacokinetics of herbal medicine after the administration
of a traditional Chinese herbal prescription of Long-Dan-Xie-
Gan-Tang (10 g kgG1, p.o.). Analytes were separated by a C18
column with a gradient system of methanol-water containing
1 mM ammonium acetate with 0.1% formic acid. The linear
ranges were 10-500 ng mLG1 for gentiopicroside, geniposide
and baicalin and 5-250 ng mLG1 for swertiamarin in biological
samples. The swertiamarin showed the lowest level of AUC
(2.5±0.1 min µg mLG1) and fell below the lower limit of
quantification (LLOQ) at 300 min in the concentration-time
curves after LDXGT administration. It was assumed that this
low level in rat plasma was due to either the low content in
LDXGT (0.22 mg gG1) or the first-pass effect. The authors also
develop a simple, precise, rapid and reliable HPTLC method for
the estimation of swertiamarin in traditional bitters and
formulations.    Aluminium-backed   silica   gel   60   F254  plates
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(20×10 cm) was used as stationary phase and ethyl acetate-
methanol-water (80:15:5, v/v) as the mobile phase.
Densitometric quantification was carried out at 246 nm.
Regression analysis of the calibration plot showed a good
linear relationship between peak-area vs. swertiamarin
concentration. Linearity was found to be in the range of
200‒1200 ng per band. The method was validated as per the
International Conference on Harmonization (ICH) guidelines.
The limit of detection (LOD) and quantification (LOQ) for
swertiamarin was found to be ~38 and ~115 ng per band,
respectively. The   developed  method  was  found  to  be 
linear (r2 = 0.9981),  precise  (Relative  Standard  Deviation
[RSD] <1.42% and <1.83% for intra-day and inter-day
precision),  accurate (mean recovery ranged from 97.69±1.46-
100.03± 0.61%), specific and robust54. The results showed a
good correlation with data obtained from HPLC analysis used
as the reference method55. Table 3 summarizes the analytical
methodology for quantitative estimation of swertiamarin and
related compound.
CONCLUSION
E. littorale   is a rich source of chemically novel
compounds such as swertiamarin  and  needs  exhaustive
screening against  new  targets  in  future.  As exemplified in
this  study,   swertiamarin   has  been  shown  to exert
beneficial effects in several models of diabetes mellitus and
cardiovascular  diseases.  The mechanism  by  which
swertiamarin reduces diabetes includes a reduction in blood
glucose, HbA1c, total cholesterol, triglycerides, LDL levels and
elevation in body weight and plasma insulin, HDL levels as
well an increase the insulin sensitivity index. It also decreases
the SGOT, SGPT and serum ALP activities. Further, it
significantly decreased serum urea and creatinine and other
parameters associated with the development of diabetes
mellitus.
SIGNIFICANCE STATEMENT
This study discovered the swertiamarin a secoiridoid
glycoside from E. littorale that can be beneficial for the
management of diabetes and related complications. This
study  will  help  the  researchers  to  uncover  the critical areas
of   phytopharmacology   and   pharmacokinetic perspective
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